Search Results - "Bavbek, Sevil E"

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy by Grünwald, Viktor, Karakiewicz, Pierre I, Bavbek, Sevil E, Miller, Kurt, Machiels, Jean-Pascal, Lee, Se-Hoon, Larkin, James, Bono, Petri, Rha, Sun Young, Castellano, Daniel, Blank, Christian U, Knox, Jennifer J, Hawkins, Robert, Anak, Oezlem, Rosamilia, Marianne, Booth, Jocelyn, Pirotta, Nicoletta, Bodrogi, István

“…Abstract Background and objectives The RECORD-1 trial established the clinical benefit of everolimus in patients with metastatic renal cell carcinoma (mRCC)…”
Get full text

Ewing's Sarcoma of the Axial System in Patients Older Than 15 Years: Dismal Prognosis Despite Intensive Multiagent Chemotherapy and Aggressive Local Treatment by Argon, Andac, Basaran, Mert, Yaman, Fulya, Dizdar, Yavuz, Sakar, Burak, Camlica, Hakan, Bavbek, Sevil E., Ozger, Harzem, Darendeliler, Emin, Onat, Haluk

“…Background: Older age and axial location of Ewing's sarcoma have been reported as unfavorable prognostic factors. Methods: The records of patients older than…”
Get full text

Induction chemotherapy with docetaxel and cisplatin is highly effective for locally advanced nasopharyngeal carcinoma by Ekenel, Meltem, Keskin, Serkan, Basaran, Mert, Ozdemir, Canan, Meral, Rasim, Altun, Musa, Aslan, Ismet, Bavbek, Sevil E

“…Summary Radiotherapy (RT) with concomitant chemotherapy (CT) has improved the therapeutic outcome of patients with locally advanced nasopharyngeal carcinoma…”
Get full text

A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas by Basaran, Mert, Bavbek, E Sevil, Saglam, Sezer, Eralp, Levent, Sakar, Burak, Atalar, Ata Can, Bilgic, Bilge, Ozger, Harzem, Onat, Haluk

“…Osteosarcoma is a rare malignancy, and patients with this disease benefit from adjuvant chemotherapy. While cisplatin, anthracyclines and ifosfamide are the…”
Get more information

Timing of death from tumor recurrence after curative gastrectomy for gastric cancer by Sakar, Burak, Karagol, Hakan, Gumus, Mahmut, Basaran, Mert, Kaytan, Esra, Argon, Andac, Ustuner, Zeki, Bavbek, Sevil E, Bugra, Dursun, Aykan, Faruk N

“…In Western literature, there are few studies investigating the predictors of early versus late recurrence after curative gastrectomy for gastric cancer. The…”
Get full text

Prognostic factors in localized aggressive non-Hodgkin's lymphoma by ALICI, Sfileyman, BAVBEK, Sevil E, KAYTAN, Esra, ERALP, Yesim, ONAT, Haluk

“…To identify the prognostic factors that specifically predict survival rates of patients with localized aggressive non-Hodgkin's lymphoma (NHL), a retrospective…”
Get full text

Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma(NPC) patients treated between 2004 and 2016: Patient and treatment characteristics and long term outcome by Altun, Musa, Kaval, Gizem, Ibis, Kamuran, Ozkaya, Kubra, Meral, Rasim, Karadeniz, Ahmet Nafiz, Sari, Murat, Ekenel, Meltem, Basaran, Mert, Bavbek, Sevil E.

“…Abstract only e17507 Background: Standard treatment of locoregionally advanced nasopharyngeal carcinoma (LRA-NPC) is CCRT with or without adjuvant chemotherapy…”
Get full text

Aggressive non-Hodgkin's lymphoma treated at the institute of oncology, Istanbul: Treatment, outcome, and prognostic factors by ALICI, Süleyman, BAVBEK, Sevil E, KAYTAN, Esra, BASARAN, Mert, ERALP, Yesim, ONAT, Haluk

“…In an unselected group of patients with aggressive non-Hodgkin's lymphoma (A-NHL) treated at our institution during a 10-year period (1989-1998), we studied…”
Get full text

Is there any prognostic importance of pretreatment serum M30 and serum M65 levels on progression-free survival of patients with metastatic renal cell carcinoma treated with first-line sunitinib? by Basaran, Mert, Yildiz, Ibrahim, Sen, Fatma, Kilic, Leyla, Keskin, Serkan, Darendeliler, Emin, Bavbek, Sevil E.

“…Abstract only e15569 Background: Effective cancer biomarkers for early detection, prognosis, or prediction of therapy response are urgently need in metastatic…”
Get full text

Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC) by Motzer, Robert John, Barrios, Carlos H., Kim, Tae Min, Falcon, Silvia, Cosgriff, Thomas, Harker, W. Graydon, Pittman, Kenneth B., Sabbatini, Roberto, Rha, Sun Young, Flaig, Thomas W., Page, Ray D., Bavbek, Sevil E., Beck, J. Thaddeus, Patel, Poulam M, Schiff, Edward, Vaury, Alexandra, Niolat, Julie, Gogov, Sven, Anak, Ozlem, Knox, Jennifer

“…Abstract only 4504 Background: Sequential SUN (tyrosine kinase inhibitor, TKI) until progression of disease (PD) followed by EVE (mTOR inhibitor) is standard…”
Get full text

Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC) by Tannock, Ian, Fizazi, Karim, Ivanov, Sergey, Thellenberg-Karlsson, Camilla, Flechon, Aude, Skoneczna, Iwona Anna, Orlandi, Francisco Jorquera, Gravis, Gwenaelle, Matveev, Vsevolod, Bavbek, Sevil E., Gil, Thierry, Viana, Luciano S., Aren, Osvaldo, Karyakin, Oleg, Elliott, Tony, Birtle, Alison J., Magherini, Emmanuelle, Petrylak, Daniel Peter, Tombal, Bertrand, Rosenthal, Mark

“…Abstract only 5002 Background: Docetaxel/prednisone is standard first-line chemotherapy for men with mCRPC. Aflibercept is a recombinant human fusion protein…”
Get full text

Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE) by Tannock, Ian, Fizazi, Karim, Ivanov, Sergei, Karlsson, Camilla Thellenberg, Flechon, Aude, Skoneczna, Iwona Anna, Orlandi, Francisco Jorquera, Gravis, Gwenaelle, Matveev, Vsevolod B., Bavbek, Sevil E., Gil, Thierry, Viana, Luciano S., Aren, Osvaldo Rudy, Karyakin, Oleg, Elliott, Tony, Birtle, Alison J., Magherini, Emmanuelle, Hatteville, Laurence, Tombal, Bertrand, Rosenthal, Mark

“…Abstract only 13 Background: Docetaxel/prednisone is standard first-line chemotherapy for mCRPC. Aflibercept (known as ziv-aflibercept in the US) is a…”
Get full text

A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results by Bavbek, Sevil E., Malik, Zafar I, Di Lorenzo, Giuseppe, Scholz, Hans-Jorg, van Oort, Inge M, Ng, Siobhan, Ozguroglu, Mustafa, Gerritsen, Winald R., Mueller, Stefan, Marttila, Timo, Antón Aparicio, Luis M., Albers, Peter, Gschwend, Jürgen E., Bensfia, Samira, Ecstein-Fraïssé, Evelyne B, Bracarda, Sergio, Heidenreich, Axel

“…Abstract only e15112 Background: In the TROPIC trial (NCT00417079), treatment with CbzP produced a statistically significant improvement in overall survival vs…”
Get full text

A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results by Bavbek, Sevil E., Malik, Zafar, Di Lorenzo, Giuseppe, Scholz, Hans-Jorg, van Oort, Inge M, Ng, Siobhan, Ozguroglu, Mustafa, Gerritsen, Winald R., Mueller, Stefan, Marttila, Timo, Anton-Aparicio, Luis M., Albers, Peter, Gschwend, Juergen, Bensfia, Samira, Ecstein-Fraïssé, Evelyne B, Bracarda, Sergio, Heidenreich, Axel

“…Abstract only 172 Background: In the Phase III TROPIC trial ( NCT00417079 ), cabazitaxel/prednisone (CbzP) improved overall survival compared with…”
Get full text

Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): A phase II study by BASARAN, Mert, BAVBEK, E. Sevil, SAKAR, Burak, ERALP, Yesim, ALICI, Süleyman, TAS, Faruk, YAMAN, Fulya, DOGAN, Öner, CAMLICA, Hakan, ONAT, Haluk

“…Epirubicin is an agent with a lower incidence of cardiotoxicity and myelotoxicity compared with doxorubicin; and it is active in patients with non-Hodgkin's…”
Get full text

LOW MORTALITY RISK IN THE TREATMENT OF SOLID PATIENTS TUMOR WITH NEUTROPENIA by Uygun, Kazim, Başaran, Mert, Yeşi̇m Eralp, Taş, Faruk, Alici, Süleyman, Şakar, Burak, Sevi̇l E Bavbek, Onat, Haluk

“…1991-1998 yılları arasında İstanbul Üniversitesi Onkoloji Enstitüsü'nde kemoterapiye bağlı febril nötropeni gelişen 61 hastada 84 atak retrospektif…”
Get full text